---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-328784"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-07-31T20:50:54+00:00"
generated_at: "2026-07-31T20:52:07.475929+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics announces conditional CEO/COO resignations and appointments pending shareholder vote

## Summary
- CEO Dirk Thye and COO Brendan Hannah tender conditional resignations effective two business days after Sept 25, 2026 special meeting, contingent on stockholder approval of three proposals.
- Board conditionally appoints Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO, effective at same time.
- Board reduces size from 5 to 4 upon Thye's resignation; intends to appoint independent director.
- Resignations and appointments tied to stockholder vote on conversion proposal, minimum price proposal, and authorized share increase to 275M.

## SEC filing metadata
- accession: 0001193125-26-328784
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-07-31T20:50:54+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/d160394d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-328784
- JSON: https://secwatch.observer/filing/0001193125-26-328784.json
- Plain text: https://secwatch.observer/filing/0001193125-26-328784.txt

## Key facts
- Executive change
  Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Operating Officer, Chief Business Officer and Chief Compliance Officer
  source text: each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm
- Executive change
  John Militello was appointed as Chief Financial Officer at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm
- Executive change
  Brigette Roberts was appointed as Chief Executive Officer at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Brigette Roberts, M.D. , age 50, was conditionally appointed as the Company’s Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm
- Executive change
  Dirk Thye resigned as Chief Executive Officer and Chief Medical Officer at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer and Chief Medical Officer
  source text: each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm
- Executive change
  Keith Fandrick was appointed as Chief Operating Officer at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: Conditional Appointments of Brigette Roberts, John Militello and Keith Fandrick
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.